Blueprint Medicines — FY2022 Earnings Presentation
13 slides from Blueprint Medicines's earnings presentation, Feb 16, 2023
Slide 1: Fourth Quarter and Full Year 2022 Financial Results
Fourth Quarter and Full Year 2022 Financial Results FEBRUARY 16, 2023
Slide 2: Agenda
Agenda ISM, indolent systemic mastocytosis ; SM, systemic mastocytosis ; AAAAI, American Academy of Allergy, Asthma, and Immunology Annual Conference. 2 Introduction and Notable 2022 Accomplishments Kate Haviland, Chief Executive Officer AYVAKIT Performance and ISM Launch Philina Lee, PhD, Chief Com
Slide 3: Forward-looking statements
Forward - looking statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding plans, strategies, timelines and expectations for Blueprint Medicines’ cur
Slide 4: Notable accomplishments in 2022 and recent period
Notable accomplishments in 2022 and recent period 4 • Doubled net product revenue YoY • ISM launch readiness preparedness • Positive pivotal data for ISM • FDA and EMA acceptance of ISM regulatory submissions • Expanded targeted protein degradation capabilities • Introduced wild - type KIT program f
Slide 5: Blueprint 2027: Precision at scale
Blueprint 2027: Precision at scale Approved medicines Disease leadership areas Late - stage clinical programs Research platforms Cumulative development candidates 2011 - 2022 2 1 2 1 14 Planned 2022 - 2027 4+ 3+ 4+ 2 25+ 2027 5 Not for promotional use
Slide 6: AYVAKIT update: full year and fourth quarter 2022 performance
AYVAKIT update: full year and fourth quarter 2022 performance 6 $21.3 $53.0 $111.0 FY 2020 FY 2021 FY 2022 >2X GLOBAL NET REVENUES ($, MILLIONS) ACHIEVED $30.1M NET REVENUES IN Q4 2022 ANTICIPATE $130 TO $140 MILLION IN AYVAKIT NET PRODUCT REVENUES IN 2023 FOR ADVANCED SM AND GIST ESTIMATED US PATIE
Slide 7: Providers estimate approximately 50% of ISM patients need a new therapy
Providers estimate approximately 50 percent of ISM patients need a new therapy 50% 55% 51% 41% 49% 0% 10% 20% 30% 40% 50% 60% 70% Community Hem/Oncs (n=20) Academic Hem/Oncs (n=19) Allergist/Immunologists (n=31) Dermatologists (n=30) Total (n=100) PERCENT OF ISM PATIENTS IN NEED OF A NEW THERAPY Eng
Slide 8: HAE: a rare disease trajectory achieving significant value over time
HAE: a rare disease trajectory achieving significant value over time 8 HEREDITARY ANGIOEDEMA • Rare disorder characterized by anaphylaxis, attacks of swelling • Treated by allergist immunologists • New specialty market established with the approval of disease modifying therapies • Market is continui
Slide 9: AYVAKIT potently and selectively targets KIT D816V
AYVAKIT potently and selectively targets KIT D816V to deliver downstream disease impacts that patients and providers care about most 9 Target the disease driver Reduce mast cell burden Impact organs and systems Reduce symptoms Improve quality of life AYVAKIT’s impact highlighted across breadth of da
Slide 10: Key anticipated portfolio milestones in 2023
Key anticipated portfolio milestones in 2023 10 Area Program Milestone Timing Mast cell disorders AYVAKIT Present registrational PIONEER trial data in indolent SM at AAAAI Annual Meeting Feb 2023 AYVAKYT Achieve EMA validation of a type II variation MAA for indolent SM AYVAKIT Achieve FDA approval a
Slide 11: Strong financial position bolstered by diversity of revenue and growing product revenue
Strong financial position bolstered by diversity of revenue and growing product revenue 11 Statement of Operations (unaudited) Three Months Ended 12/31/2022 Three Months Ended 12/31/2021 FY Ended 12/31/2022 FY Ended 12/31/2021 Total revenue $38.8M $107.0M $204.0M $180.1M Net product sales Collaborat
Slide 12: Full year 2023 financial guidance
Full year 2023 financial guidance 12 FY 2022 Actuals FY 2023 Guidance FY 2023 Commentary AYVAKIT Net Product Revenue $111.0M $130M - $140M Moderate growth in AdvSM revenue; additional revenue expected from anticipated ISM launch not included in guidance Existing Collaboration and License Revenue $93
Slide 13: Thank You
(Sblueprint: Thank You